Immix Biopharma (NASDAQ:IMMX) Upgraded to “Hold” at Wall Street Zen

Immix Biopharma (NASDAQ:IMMX) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Immix Biopharma in a research report on Thursday, January 22nd. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $8.00.

Immix Biopharma Price Performance

Shares of NASDAQ:IMMX opened at $5.83 on Friday. The stock has a market cap of $308.76 million, a price-to-earnings ratio of -7.57 and a beta of 0.31. Immix Biopharma has a 12 month low of $1.34 and a 12 month high of $7.73. The stock’s 50 day moving average price is $5.30 and its 200 day moving average price is $3.60.

Immix Biopharma (NASDAQ:IMMX) last posted its quarterly earnings data on Friday, November 7th. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.05). On average, sell-side analysts expect that Immix Biopharma will post -0.87 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Velan Capital Investment Management LP acquired a new stake in Immix Biopharma during the 2nd quarter worth about $52,000. Tocqueville Asset Management L.P. lifted its position in shares of Immix Biopharma by 37.4% in the third quarter. Tocqueville Asset Management L.P. now owns 40,250 shares of the company’s stock worth $84,000 after purchasing an additional 10,950 shares in the last quarter. Imprint Wealth LLC acquired a new stake in shares of Immix Biopharma during the third quarter worth approximately $141,000. Concurrent Investment Advisors LLC purchased a new position in Immix Biopharma during the fourth quarter valued at approximately $143,000. Finally, United Capital Financial Advisors LLC acquired a new position in Immix Biopharma in the 3rd quarter valued at approximately $148,000. Hedge funds and other institutional investors own 11.26% of the company’s stock.

About Immix Biopharma

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.